| Name | SB 204990 |
| Description | SB 204990 is a lactone prodrug of SB-201076, a potent and specific ATP citrate lyase inhibitor. |
| In vitro | METHODS: Primary hepatocytes were treated with SB-204990 (10 μM, 16 hours) under different experimental conditions to determine the effects occurring early after exposure to the Acly inhibitor SB-204990.
RESULTS Phosphorylation of pThr 172 Ampk and pSer 79 Acc was reduced in primary hepatocytes treated with SB-204990 for 16 hours, while markers of Sirt1 or mTOR activity were absent. [1] |
| In vivo | METHODS: Mice were treated with SB-204990 (30 mg/kg body weight; oral gavage; treatment for 3 hours) to determine whether SB-204990 could induce effects in mitochondria in vivo.
RESULTS Freshly isolated liver mitochondria from mice showed blocking and limiting effects on ADP-induced and FCCP-induced increases in OCR, respectively. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.84 mM), Sonication is recommended. DMSO : 242 mg/mL (621.68 mM), Sonication is recommended. H2O : 10 mg/mL (25.69 mM), Sonication is recommended.
|
| Keywords | SB-204990 | SB204990 | SB 204990 | Inhibitor | inhibit | ATPCitrateLyase | ATP Citrate Lyase | ACLY |
| Inhibitors Related | BMS-303141 | ACLY Inhibitor 7 | Hydroxycitric acid tripotassium hydrate | (-)-Hydroxycitric acid lactone | MEDICA16 | EVT0185 | 2-Furoic acid | Bempedoic acid | NDI-091143 | Citric acid trilithium salt tetrahydrate | (-)-Hydroxycitric acid | Hydroxycitric acid |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |